Literature DB >> 12876414

Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study.

Georg Brabant1, Alexander von zur Mühlen, Christian Wüster, Michael B Ranke, Jürgen Kratzsch, Wieland Kiess, Jean-Marie Ketelslegers, Lars Wilhelmsen, Lena Hulthén, Bernhard Saller, Anders Mattsson, Jürgen Wilde, Rudolf Schemer, Peter Kann.   

Abstract

BACKGROUND: Analysis of insulin-like growth factor I in serum (S-IGF-I) is an integral component in the diagnosis of GH-related disorders and is going to be of interest in the diagnosis and follow-up of many disorders. The objective of the present study was to develop cross-sectional reference values for S-IGF-I measured by an automated chemiluminescence immunoassay (Nichols Advantage).
METHODS: The study included samples from 3,961 healthy subjects (2,201 males, 1,760 females) aged 1 month to 88 years. Six laboratories were involved in this study and the samples were analyzed by one of seven automated immunoassay systems run in these laboratories. For data analysis, polynomial age and sex-specific models were fitted after transformation of S-IGF-I values.
RESULTS: The results show the well-known age dependency of S-IGF-I levels. At ages <20, higher S-IGF-I levels were seen in girls with an estimated mean peak of 410 microg/l at age 14 and an estimated mean peak of 382 microg/l at age 16 in boys. Thereafter, a rapid decrease was seen to approximately 25 years of age, followed by a slow age-dependent decrease. In adulthood, S-IGF-I in males were slightly, but significantly higher than in females. It could be shown that the mean values of some reference sample subgroups differed significantly from the total mean. However, the multicenter approach used in this study reduces the impact of systematic population, sample handling and laboratory differences on the calculated reference mean.
CONCLUSION: The present study establishes age- and sex-specific reference values for a fully automated immunoassay system based on a large population of healthy subjects. The established reference values may be used for this immunoassay system in different laboratories provided that the systematic difference between systems is low. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876414     DOI: 10.1159/000071871

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  85 in total

1.  Detailed studies of growth hormone secretion in cystinosis patients.

Authors:  Martine T P Besouw; Maria Van Dyck; Inge Francois; Elke Van Hoyweghen; Elena N Levtchenko
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

2.  The metabolic consequences of thyroxine replacement in adult hypopituitary patients.

Authors:  Helena Filipsson Nyström; Ulla Feldt-Rasmussen; Ione Kourides; Vera Popovic; Maria Koltowska-Häggström; Björn Jonsson; Gudmundur Johannsson
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 3.  Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Authors:  David R Clemmons
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 4.  Body composition and skeletal health: too heavy? Too thin?

Authors:  Alexander Faje; Anne Klibanski
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

Review 5.  Anterior pituitary hormone replacement therapy--a clinical review.

Authors:  Christoph J Auernhammer; George Vlotides
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

6.  Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study.

Authors:  Vivien Bonert; John Carmichael; Zengru Wu; James Mirocha; Daniel A Perez; Nigel J Clarke; Richard E Reitz; Michael J McPhaul; Adam Mamelak
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

7.  Failure of antibody response to polysaccharide antigen in treated panhypopituitary adults.

Authors:  A Mukherjee; M Helbert; W D J Ryder; R Borrow; J R E Davis; S M Shalet
Journal:  Clin Exp Immunol       Date:  2009-02-10       Impact factor: 4.330

8.  Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.

Authors:  E Ghigo; B M K Biller; A Colao; I A Kourides; N Rajicic; R K Hutson; L De Marinis; A Klibanski
Journal:  J Endocrinol Invest       Date:  2009-12-04       Impact factor: 4.256

9.  Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Authors:  R Cozzi; R Attanasio; S Grottoli; G Pagani; P Loli; V Gasco; A M Pedroncelli; M Montini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

10.  Early signs of metabolic syndrome in pediatric central nervous system tumor survivors after high-dose chemotherapy and autologous stem-cell transplantation and radiation.

Authors:  Chantel Cacciotti; Muhammad Ali; Ute Bartels; Jonathan D Wasserman; Erilda Kapllani; Joerg Krueger; Eric Bouffet; Tal Schechter
Journal:  Childs Nerv Syst       Date:  2020-11-18       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.